GSK Petitions India’s NPPA For Change In Excise Tax
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline has filed with India's drug-pricing authority to exclude excise and other taxes from the basis for capping retail prices for specific brands. The effort centers on GSK's Vozet (levocetirizine) for preventing allergies. The company said the 2005 change from levying the excise tax on the wholesale to the retail price has led to a heavier burden on drug makers. The GSK filing also cited other problems with recent changes made by the National Pharmaceutical Pricing Authority. (Click here for more